Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Rachel Haurwitz, PhD, the company's president and CEO, will deliver a corporate update presentation on Thursday, January 16, 2025, at 10:30 am PST.
The presentation will be accessible via webcast through the Events page on Caribou's website, with recordings remaining available for 30 days following the event.
Caribou Biosciences (Nasdaq: CRBU), una società biofarmaceutica in fase clinica specializzata nell'editing genetico CRISPR, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference. Rachel Haurwitz, PhD, presidente e CEO della società, presenterà un aggiornamento aziendale giovedì 16 gennaio 2025, alle 10:30 PST.
La presentazione sarà accessibile tramite webcast attraverso la pagina Eventi sul sito di Caribou, con registrazioni disponibili per 30 giorni dopo l'evento.
Caribou Biosciences (Nasdaq: CRBU), una empresa biofarmacéutica en etapa clínica especializada en la edición genética CRISPR, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. Rachel Haurwitz, PhD, presidenta y directora ejecutiva de la empresa, ofrecerá una presentación de actualización corporativa el jueves 16 de enero de 2025, a las 10:30 a.m. PST.
La presentación será accesible a través de un webcast en la página de Eventos del sitio web de Caribou, con grabaciones disponibles durante 30 días después del evento.
Caribou Biosciences (Nasdaq: CRBU), 임상 단계의 CRISPR 유전자 편집 바이오 제약 회사가 제43회 연례 J.P. Morgan Healthcare Conference에 참여한다고 발표했습니다. Rachel Haurwitz, PhD, 회사의 사장 겸 CEO는 2025년 1월 16일 목요일, 오전 10:30 PST에 기업 업데이트 발표를 할 예정입니다.
발표는 Caribou 웹사이트의 이벤트 페이지를 통해 웹캐스트로 접근할 수 있으며, 이벤트 후 30일 동안 녹화본이 제공됩니다.
Caribou Biosciences (Nasdaq: CRBU), une entreprise biopharmaceutique en phase clinique spécialisée dans l'édition génomique CRISPR, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Rachel Haurwitz, PhD, la présidente et PDG de l'entreprise, présentera une mise à jour sur la société jeudi 16 janvier 2025, à 10h30 PST.
La présentation sera accessible en webdiffusion via la page Événements sur le site de Caribou, avec des enregistrements disponibles pendant 30 jours après l'événement.
Caribou Biosciences (Nasdaq: CRBU), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf CRISPR-Gentechnologie spezialisiert ist, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference angekündigt. Rachel Haurwitz, PhD, die Präsidentin und CEO des Unternehmens, wird am Donnerstag, den 16. Januar 2025, um 10:30 Uhr PST eine Unternehmenspräsentation halten.
Die Präsentation wird über einen Webcast auf der Veranstaltungsseite von Caribou zugänglich sein, wobei Aufzeichnungen 30 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST.
For more information and a link to the live webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.
About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
FAQ
When is Caribou Biosciences (CRBU) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will the CRBU J.P. Morgan Healthcare Conference webcast be available?
Who is presenting for CRBU at the 2025 J.P. Morgan Healthcare Conference?
Where can investors access CRBU's J.P. Morgan Healthcare Conference presentation?
